Menu Search
Equities

Exagen Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
E08A:FRA

Exagen Inc

Actions
  • Price (EUR)2.74
  • Today's Change-0.14 / -4.86%
  • Shares traded17.00
  • 1 Year change-39.65%
  • Beta1.8907
Data delayed at least 15 minutes, as of Feb 12 2026 07:17 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.

  • Revenue in USD (TTM)63.60m
  • Net income in USD-19.04m
  • Incorporated2003
  • Employees203.00
  • Location
    Exagen Inc1261 Liberty WayVISTA 92081United StatesUSA
  • Phone+1 (760) 560-1501
  • Fax+1 (302) 655-5049
  • Websitehttps://exagen.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.